Evidence map›Paper›PMID 39092114›Full record

ArticleChemical science2024

A first-in-class dual-chelator theranostic agent designed for use with imaging-therapy radiometal pairs of different elements.

James L Wood, Saikat Ghosh, Zachary H Houston, Nicholas L Fletcher, James Humphries, Karine Mardon, Dewan T Akhter, William Tieu, Alesia Ivashkevich, Michael P Wheatcroft and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Chemical science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Synthesis and in vitro characterization of [EJNMMI radiopharmacy and chemistry · 2025
    Article
  7. Radiotheranostic landscape: A review of clinical and preclinical development.European journal of nuclear medicine and molecular imaging · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

James L WoodThe University of Sydney, School of Medical Sciences New South Wales 2006 Australia rachel.codd@sydney.edu.au.ORCID https://orcid.org/0000-0001-8755-779X
Saikat GhoshCentre for Advanced Imaging (CAI), Australian Institute for Bioengineering and Nanotechnology (AIBN) and ARC Training Centre for Innovation in Biomedical Imaging Technology, The University of Queensland Brisbane Queensland 4072 Australia.ORCID https://orcid.org/0000-0003-0937-6242
Zachary H HoustonCentre for Advanced Imaging (CAI), Australian Institute for Bioengineering and Nanotechnology (AIBN) and ARC Training Centre for Innovation in Biomedical Imaging Technology, The University of Queensland Brisbane Queensland 4072 Australia.ORCID https://orcid.org/0000-0001-9738-4917
Nicholas L FletcherCentre for Advanced Imaging (CAI), Australian Institute for Bioengineering and Nanotechnology (AIBN) and ARC Training Centre for Innovation in Biomedical Imaging Technology, The University of Queensland Brisbane Queensland 4072 Australia.ORCID https://orcid.org/0000-0002-2993-833X
James HumphriesCentre for Advanced Imaging (CAI), Australian Institute for Bioengineering and Nanotechnology (AIBN) and ARC Training Centre for Innovation in Biomedical Imaging Technology, The University of Queensland Brisbane Queensland 4072 Australia.
Karine MardonCentre for Advanced Imaging (CAI), Australian Institute for Bioengineering and Nanotechnology (AIBN) and ARC Training Centre for Innovation in Biomedical Imaging Technology, The University of Queensland Brisbane Queensland 4072 Australia.
Dewan T AkhterCentre for Advanced Imaging (CAI), Australian Institute for Bioengineering and Nanotechnology (AIBN) and ARC Training Centre for Innovation in Biomedical Imaging Technology, The University of Queensland Brisbane Queensland 4072 Australia.
William TieuMolecular Imaging and Therapy Research Unit (MITRU), South Australian Health and Medical Research Institute (SAHMRI) Adelaide Australia.
Alesia IvashkevichTelix Pharmaceuticals Limited North Melbourne Victoria 3051 Australia.
Michael P WheatcroftTelix Pharmaceuticals Limited North Melbourne Victoria 3051 Australia.
Kristofer J ThurechtCentre for Advanced Imaging (CAI), Australian Institute for Bioengineering and Nanotechnology (AIBN) and ARC Training Centre for Innovation in Biomedical Imaging Technology, The University of Queensland Brisbane Queensland 4072 Australia.ORCID https://orcid.org/0000-0002-4100-3131
Rachel CoddThe University of Sydney, School of Medical Sciences New South Wales 2006 Australia rachel.codd@sydney.edu.au.ORCID https://orcid.org/0000-0002-2703-883X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A covalent adduct of DFOB and DOTA separated by a l-lysine residue (DFOB-l-Lys-

Identifiers

PMID39092114
PMCPMC11290327

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.